Our results focusing on the diseased AMD cerebellum indicate that neonatal AAV6 treatment also markedly ameliorates reactive astroglial response (GFAP) and reduces lysosomal storage (LAMP1) compared to untreated AMD mice. This evidence concerns the gene LAMP1 and age-related macular degeneration.